Avid Radiopharms Inc Company Profile
What is the competitive landscape for AVID RADIOPHARMS INC
AVID RADIOPHARMS INC has two approved drugs.
There are three US patents protecting AVID RADIOPHARMS INC drugs.
Summary for Avid Radiopharms Inc
| US Patents: | 3 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Avid Radiopharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-001 | May 28, 2020 | DISCN | Yes | No | 8,932,557 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-003 | Jul 1, 2022 | RX | Yes | Yes | 8,932,557 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-004 | Oct 13, 2023 | RX | Yes | Yes | 8,506,929 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Avid Radiopharms Inc | TAUVID | flortaucipir f-18 | SOLUTION;INTRAVENOUS | 212123-004 | Jul 1, 2022 | RX | Yes | Yes | 8,932,557 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Avid Radiopharms Inc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 2018030 | ⤷ Start Trial |
| Cyprus | 1125258 | ⤷ Start Trial |
| Cyprus | 1113048 | ⤷ Start Trial |
| Portugal | 2247558 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Avid Radiopharms Inc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1999109 | 2013/028 | Ireland | ⤷ Start Trial | PRODUCT NAME: FLORBETAPIR (18F), OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/12/805 20130114 |
| 1999109 | C01999109/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: SWISSMEDIC 62897 09.01.2014 |
| 1999109 | PA2013016 | Lithuania | ⤷ Start Trial | PRODUCT NAME: FLORBETAPIRUM; REGISTRATION NO/DATE: EU/1/12/805 20130114 |
| 1999109 | SPC/GB13/040 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: FLORBETAPIR (18F) ((E)-4-(2-(6-(2-(2-(2-((18F)-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL(18F); REGISTERED: UK EU/1/12/805 20130117 )VINYL)-N-METHYL BENZENAMINE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY FLORBETAPIR |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
